A sensitivity analysis was conducted controlling for the use of cholinesterase inhibitors, since these might moderate the relationship between cognitive impairments and autonomic symptoms: use of cholinesterase inhibitors was associated with significantly lower total COMPASS and secretomotor symptom severities (95% CI: 19%–61% reduction in COMPASS symptom reported severity, 22%–53% reduction in secretomotor symptom reported severity). Here, BCHE is linked to Cognitive impairment.